NEKTAR THERAPEUTICS
Small molecule and biologic drugs for autoimmune and inflammatory diseases
- Sector
- Biotech
- Headquarters
- San Francisco, CA
- Latest Form D
- $30M, Mar 2024
- Total capital
- $880M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $880M
- 2 Form D · last Mar 2024
- 31 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 27
- 13 pending · first 2021
- Rank in peer group#6 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$30M
- Private capital raisedForm D · SEC · 1st filing$850M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#6 · top 1%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Christopher A. KueblerDirectorNamed in SEC Form D filings
- Dennis L. WingerDirectorNamed in SEC Form D filings
- Diana M BrainardDirectorNamed in SEC Form D filings
- Gil M. LabrucherieExecutive OfficerNamed in SEC Form D filings
- Howard W RobinExecutive Officer, DirectorNamed in SEC Form D filings
- Jeff R. AjerDirectorNamed in SEC Form D filings
Show all 18 people
- Jeffrey R AjerDirectorNamed in SEC Form D filings
- Jillian B. ThomsenExecutive OfficerNamed in SEC Form D filings
- John K. NicholsonExecutive OfficerNamed in SEC Form D filings
- Jonathan A ZalevskyExecutive OfficerNamed in SEC Form D filings
- Lutz A. LingnauDirectorNamed in SEC Form D filings
- Maninder K. HoraExecutive OfficerNamed in SEC Form D filings
- Mark A WilsonExecutive OfficerNamed in SEC Form D filings
- Robert B ChessDirectorNamed in SEC Form D filings
- Roy A WhitfieldDirectorNamed in SEC Form D filings
- R. Scott R. GreerDirectorNamed in SEC Form D filings
- Sandra W GardinerExecutive OfficerNamed in SEC Form D filings
- Stephen K. DobersteinExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 27 granted of 40- GrantedConjugates Of An IL-7 Moiety And A PolymerUSPTOUS 12,629,407
- PendingConjugates Of An IL-2 Moiety And A PolymerUSPTOApplication 19047443
- PendingPolymer Engineered Forms Of Interferon-gamma And Methods Of UseUSPTOApplication 18578526
Show all 40 patent records
- Conjugates Of An IL-7 Moiety And A PolymerMay 19, 2026 · US 12,629,407Granted
- Conjugates Of An IL-2 Moiety And A PolymerOct 2, 2025 · Application 19047443Pending
- Polymer Engineered Forms Of Interferon-gamma And Methods Of UseAug 28, 2025 · Application 18578526Pending
- Conjugates Of A Factor Viii Moiety Having An Oxime-containing LinkageJun 10, 2025 · US 12,324,828Granted
- Adenosine 2 Receptor AntagonistsJun 10, 2025 · US 12,325,708Granted
- Conjugates Of An IL-2 Moiety And A PolymerMar 11, 2025 · US 12,247,059Granted
- Combination Of An IL-2RBETA-SELECTIVE Agonist And A Long-acting IL-15 AgonistFeb 25, 2025 · US 12,233,104Granted
- Multi-arm Polymer Conjugates Of Tlr Agonist Compounds And Related Immunotherapeutic Treatment MethodsFeb 4, 2025 · US 12,214,045Granted
- Long-acting INTERLEUKIN-15 Receptor Agonists And Related Immunotherapeutic Compositions And MethodsDec 26, 2024 · Application 18735818Pending
- Histidine-selective Polymer ReagentsSep 12, 2024 · Application 18570610Pending
- Immunotherapeutic Tumor Treatment MethodAug 6, 2024 · US 12,054,553Granted
- Long-acting INTERLEUKIN-15 Receptor Agonists And Related Immunotherapeutic Compositions And MethodsJul 16, 2024 · US 12,036,283Granted
- Immunotherapeutic Tumor Treatment MethodJul 9, 2024 · US 12,030,940Granted
- Methods Of Preparing A Monodisperse Oligo(ethylene Glycol) Reagent CompositionJun 25, 2024 · US 12,016,952Granted
- Method Of Making Releasable Polymeric ReagentsMar 19, 2024 · US 11,932,726Granted
- Alkoxylation MethodsDec 5, 2023 · US 11,834,553Granted
- Multi-arm Polymeric Prodrug Conjugates Of Taxane-based CompoundsNov 14, 2023 · US 11,813,241Granted
- Multi-arm Polymer Conjugates Of Tlr Agonist Compounds And Related Immunotherapeutic Treatment MethodsSep 5, 2023 · US 11,744,898Granted
- Multi-arm Polymeric Alkanoate ConjugatesJun 13, 2023 · US 11,672,776Granted
- Polymeric Alpha-hydroxy Aldehyde And Ketone Reagents And Conjugation MethodApr 25, 2023 · US 11,634,540Granted
- Conjugates Of A Factor Viii Moiety Having An Oxime-containing LinkageApr 18, 2023 · US 11,628,205Granted
- Polymer Derivatives Having Particular Atom ArrangementsApr 13, 2023 · Application 17818687Pending
- Multi-arm Polymeric Prodrug Conjugates Of Pemetrexed-based CompoundsMar 28, 2023 · US 11,612,662Granted
- Oligomer-corticosteroid ConjugatesOct 11, 2022 · US 11,464,788Granted
- Polymer Derivatives Having Particular Atom ArrangementsSep 20, 2022 · US 11,446,385Granted
- Polymer-sunitinib ConjugatesAug 23, 2022 · US 11,419,943Granted
- Polymer-des-ethyl Sunitinib ConjugatesAug 9, 2022 · US 11,406,618Granted
- Pharmaceutical Composition Comprising A Polymer-polyeptide ConjugateMay 12, 2022 · Application 17586495Pending
- Multi-arm Polymer ProdrugsMar 17, 2022 · Application 17535385Pending
- Oligomer-corticosteroid ConjugatesMar 10, 2022 · Application 17527910Pending
- Conjugates Having A Degradable Linkage And Polymeric Reagents Useful In Preparing Such ConjugatesMar 8, 2022 · US 11,266,742Granted
- N-METHYL-N-(1-PHENYL-2-(1-PYRROLIDINYL)ETHYL)-2-AMINOPHENYLACETAMIDE Derivatives Agonists For The Kappa Opioid ReceptorFeb 8, 2022 · US 11,241,415Granted
- Polymeric Alpha-hydroxy Aldehyde And Ketone Reagents And Conjugation MethodJan 11, 2022 · US 11,220,575Granted
- Polymer-factor Viii Moiety ConjugatesDec 30, 2021 · Application 17470811Pending
- Methods Of Treating CYP2D6 Alternative MetabolizersDec 30, 2021 · Application 17319962Pending
- Long-acting INTERLEUKIN-15 Receptor Agonist In Combination With Another Pharmacologically Active AgentDec 23, 2021 · Application 17292135Pending
- Combinations for Treating CancerNov 18, 2021 · Application 17291069Pending
- Method For Preparing Functionalized Polymers From Polymer AlcoholsNov 11, 2021 · Application 17165958Pending
- Method Of Making A Water-soluble Polymer-factor Viii Moiety ConjugateOct 12, 2021 · US 11,141,465Granted
- Chemically Modified Small MoleculesSep 28, 2021 · US 11,129,794Granted
Related companies, and why
- Stylus MedicineSimilar federal contract value in Biotech · null in contracts
- HYKU BIOSCIENCES INC.Similar federal contract value in Biotech · null in contracts
- HUMACYTE, INC.Similar federal contract value in Biotech · null in contracts
- Natglycan, LLCSimilar federal contract value in Biotech · null in contracts
- Tourmaline BioSimilar federal contract value in Biotech · null in contracts
- MyOmeSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .